MktsMarkets

Intensity Therapeutics, Inc.
NASDAQ: INTSKey statistics
INTS News
Stories mentioning INTS from around the web — every one is an open thread, so give it a like or add your take.
Loading news…
Financial statements
As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.
| Line item | Q1 '26Mar 31 | Q4 '25Dec 31 | Q3 '25Sep 30 | Q2 '25Jun 30 | Q1 '25Mar 31 | Q4 '24Dec 31 | Q3 '24Sep 30 | Q2 '24Jun 30 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | ||||||||
| Cost of Goods Sold | ||||||||
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | ||||||||
| Research & Development | 1,195 | 1,502 | 1,553 | 1,541 | 2,189 | 1,967 | 2,151 | 3,563 |
| Sales General & Admin | ||||||||
| Total Operating Expenses | 2,526 | 3,140 | 2,733 | 2,705 | 3,394 | 3,203 | 3,570 | 5,069 |
| Operating Income (Loss) | (2,526) | (3,140) | (2,733) | (2,705) | (3,394) | (3,203) | (3,570) | (5,069) |
| Interest Income | 94.00 | 89.00 | 59.00 | 17.00 | 15.00 | 28.00 | 48.00 | 98.00 |
| Interest Expense | ||||||||
| Other Expense | (2.00) | 0.00 | 3.00 | 151.00 | 32.00 | (6.00) | 9.00 | 0.00 |
| Pretax Income | ||||||||
| Tax Provision | ||||||||
| Net Income (Loss) | (2,434) | (3,051) | (2,671) | (2,537) | (3,347) | (3,181) | (3,513) | (4,971) |
| Earnings Per Share (Basic) | (0.96) | (2.25) | (0.06) | (0.13) | (5.51) | (5.72) | (0.25) | (0.36) |
| Earnings Per Share (Diluted) | (0.96) | (2.25) | (0.06) | (0.13) | (5.51) | (5.72) | (0.25) | (0.36) |
| Weighted Average Shares Outstanding (Basic) | 2,534 | 1,356 | 43,043 | 18,868 | 607.00 | 556.00 | 13,805 | 13,712 |
| Weighted Average Shares Outstanding (Diluted) | 2,534 | 1,356 | 43,043 | 18,868 | 607.00 | 556.00 | 13,805 | 13,712 |
Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.
About INTS
Intensity Therapeutics, Inc. (NASDAQ: INTS) is a stock listed on the Nasdaq Stock Market under the ticker symbol INTS. It last traded at $3.08 (Nov 13, 2026, 9:30 AM ET), down 0.7% on the day. That gives Intensity Therapeutics a market capitalisation of $10.6M.
Over the past 52 weeks INTS has traded between $2.80 and $15.00.
For the quarter ended Mar 31, 2026 it reported a net loss of $2.4M.
| Quarter ended | Revenue | Net income |
|---|---|---|
| Mar 31, 2026 | — | -$2.4M |
| Dec 31, 2025 | — | -$3.1M |
| Sep 30, 2025 | — | -$2.7M |
| Jun 30, 2025 | — | -$2.5M |
From Intensity Therapeutics’s quarterly (10-Q) filings, in US dollars.
Take a break — play a market game
Seven free games built around the markets. No download, no sign-up: they run right here in your browser.
Latest News
Market news from around the web — every story is an open thread, so give it a like or add your take.
Loading news…